

## Bangladesh

### Support for Vaccine: Inactivated Polio Vaccine (IPV) This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Bangladesh																					
2. Vaccine grant number:	1418-BGD-25b-X, 1518-BGD-25b-X, 19-BGD-25d-X, 20-BGD-25b-X																					
3. Date of Decision Letter:	30/09/2019																					
4. Date of the Partnership Framework Agreement:	24 June 2013																					
5. Programme title:	New Vaccine Support (NVS), Fractional Inactivated Polio Virus, Routine																					
6. Vaccine type:	Fractional Inactivated Polio Virus																					
7. Requested product presentation and formulation of vaccine:	Fractional Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID																					
8. Programme Duration: <sup>1</sup>	2014-2020																					
9. Programme Budget (indicative): <sup>2</sup>	(subject to the terms of the Partnership Framework Agreement)																					
	2014-2019	2020	2021	2022	2023	2024	Total <sup>2</sup>															
Programme Budget (US\$)	20,701,909	3,874,500	-	-	-	-	24,576,409															
10. Vaccine introduction grant	<table border="1"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2014</td> <td>14-BGD-08h-Y</td> <td>2,498,000</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>14 August 2014</td> <td>2,498,000</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2014	14-BGD-08h-Y	2,498,000	Disbursement		Disbursement date	Amount (US\$)	14 August 2014	2,498,000
Approval																						
Year	Grant Number	Amount (US\$)																				
2014	14-BGD-08h-Y	2,498,000																				
Disbursement																						
Disbursement date	Amount (US\$)																					
14 August 2014	2,498,000																					
11. Product switch grant	Not applicable																					

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

**12. Indicative Annual Amounts:**<sup>3</sup> (subject to the terms of the Partnership Framework Agreement)

Type of supplies to be purchased with Gavi funds	2014-2019	2020	2021
Number of vaccine doses		1,427,500	-
Annual Amounts (US\$)	20,701,909	3,874,500	-

**13. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**14. Self-procurement:** Not applicable

**15. Co-financing obligations:**

**Not applicable**

Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

**16. Operational support for campaigns:**

**Not applicable**

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
<ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> </ul>	31 March 2020
<ul style="list-style-type: none"> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> </ul>	15 May 2020
<ul style="list-style-type: none"> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	N/A
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

**18. Financial clarifications:** Country shall provide the following clarifications to Gavi\*:

Not applicable

\* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

**19. Other conditions:**

Not applicable

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

*Signed by,*

**On behalf of Gavi**



Thabani Maphosa

Managing Director, Country Programmes

30/09/2019